F-Secure Oyj
5.3.2021 15:01:47 CET | Globenewswire | Press release
F-Secure Corporation, Stock Exchange Release, 5 March 2021, at 16.00 EET
F-Secure Corporation – Manager’s Transactions – Juha Kivikoski
F-Secure Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Kivikoski, Juha
Position: Other senior manager
Issuer: F-Secure Oyj
LEI: 743700ATXLT0MFCHXT16
Notification type: INITIAL NOTIFICATION
Reference number: 743700ATXLT0MFCHXT16_20210226150208_2
____________________________________________
Transaction date: 2021-03-03
Venue not applicable
Instrument type: SHARE
ISIN: FI0009801310
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION
Transaction details
(1): Volume: 4,050 Unit price: EUR
Aggregated transactions
(1): Volume: 4,050 Volume weighted average price: EUR
Contact information:
Henri Kiili, Investor Relations and Corporate Finance Director, F-Secure Corporation
+358 40 840 5450
investor-relations@f-secure.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
MoonLake Immunotherapeutics AG22.2.2026 17:00:00 CET | Press release
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Unlimit Group A/S21.2.2026 16:02:21 CET | Pressemeddelelse
Ændring i ledelsen
WOAHRAE21.2.2026 04:25:49 CET | Press release
‘The Jay Walker Podcast’ to premiere Globally on Tubi this summer
Equinox Gold Corp.20.2.2026 23:10:27 CET | Press release
Equinox Gold Announces Filing of 2025 Audited Financial Statements
Teva Pharmaceutical Industries Ltd20.2.2026 20:43:11 CET | Press release
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
